Cargando…

Effect of a genomic classifier test on clinical practice decisions for patients with high-risk prostate cancer after surgery

OBJECTIVES: To evaluate the impact of a genomic classifier (GC) test for predicting metastasis risk after radical prostatectomy (RP) on urologists' decision-making about adjuvant treatment of patients with high-risk prostate cancer. SUBJECTS AND METHODS: Patient case history was extracted from...

Descripción completa

Detalles Bibliográficos
Autores principales:	Badani, Ketan K, Thompson, Darby J, Brown, Gordon, Holmes, Daniel, Kella, Naveen, Albala, David, Singh, Amar, Buerki, Christine, Davicioni, Elai, Hornberger, John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2015
Materias:	Urological Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4371645/ https://www.ncbi.nlm.nih.gov/pubmed/24784420 http://dx.doi.org/10.1111/bju.12789

Ejemplares similares

Impact of a genomic classifier of metastatic risk on postoperative treatment recommendations for prostate cancer patients: a report from the DECIDE study group
por: Badani, Ketan, et al.
Publicado: (2013)

A four‐group urine risk classifier for predicting outcomes in patients with prostate cancer
por: Connell, Shea P., et al.
Publicado: (2019)

Transcriptome-Wide Detection of Differentially Expressed Coding and Non-Coding Transcripts and Their Clinical Significance in Prostate Cancer
por: Erho, Nicholas, et al.
Publicado: (2012)

Evaluating the Clinical Impact of a Genomic Classifier in Prostate Cancer Using Individualized Decision Analysis
por: Lobo, Jennifer Mason, et al.
Publicado: (2015)

Impact of Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography on the Therapeutic Decision of Prostate Carcinoma Primary Staging: A Retrospective Analysis at the Brazilian National Public Health System
por: da Silva, Anna Carolina Borges, et al.
Publicado: (2023)

Should Patients with Renal Cell Carcinoma and Pathological Nodal Invasion Be Classified As Having Stage IV Disease?
por: Yu, Kai-Jie, et al.
Publicado: (2023)

Decision analytic cost-effectiveness model to compare prostate cryotherapy to androgen deprivation therapy for treatment of radiation recurrent prostate cancer
por: Boyd, Kathleen A, et al.
Publicado: (2015)

Resveratrol in prostate diseases
por: Salagierski, Maciej
Publicado: (2013)

Inflammatory changes and the prostate
por: Soloway, Mark S.
Publicado: (2013)

Obesity and prostate cancer research
por: Van den Broeck, Thomas, et al.
Publicado: (2013)

Best practice in active surveillance for men with prostate cancer: a Prostate Cancer UK consensus statement
por: Merriel, Samuel W.D., et al.
Publicado: (2019)

Thrombospondin 1 and cathepsin D improve prostate cancer diagnosis by avoiding potentially unnecessary prostate biopsies
por: Steuber, Thomas, et al.
Publicado: (2018)

Correlation Between Urodynamic and Clinical Diagnoses in Classifying the Type of Urinary Incontinence in Women
por: Palaiologos, Konstantinos, et al.
Publicado: (2019)

Prostate cancer upgrading with serial prostate magnetic resonance imaging and repeat biopsy in men on active surveillance: are confirmatory biopsies still necessary?
por: Osses, Daniël F., et al.
Publicado: (2020)

Education concerning carcinoma of prostate and its early detection
por: Dutkiewcz, Sławomir, et al.
Publicado: (2011)

Prostate cancer recurrence – new prognostic factors are needed
por: Wajsman, Zew
Publicado: (2013)

Androgen deprivation therapy for prostate cancer and risk of dementia
por: Robinson, David, et al.
Publicado: (2019)

Models predicting survival to guide treatment decision-making in newly diagnosed primary non-metastatic prostate cancer: a systematic review
por: Thurtle, David, et al.
Publicado: (2019)

β-catenin as a prognostic factor for prostate cancer (PCa)
por: Nowicki, Andrzej, et al.
Publicado: (2012)

Outcome of surgery in locally advanced pT3a prostate cancer
por: Milonas, Daimantas, et al.
Publicado: (2011)

Complication rates after prostate biopsy according to the number of sampled cores
por: Madej, Adam, et al.
Publicado: (2012)

Predicting biochemical recurrence and prostate cancer‐specific mortality after radical prostatectomy: comparison of six prediction models in a cohort of patients with screening‐ and clinically detected prostate cancer
por: Remmers, Sebastiaan, et al.
Publicado: (2019)

United in Fight against prOstate cancer (UFO) registry: first results from a large, multi‐centre, prospective, longitudinal cohort study of advanced prostate cancer in Asia
por: Uemura, Hirotsugu, et al.
Publicado: (2020)

Active surveillance for low-risk prostate cancer: well established, yet avoided?
por: Sosnowski, Roman, et al.
Publicado: (2022)

Distribution of prostate cancer recurrences on gallium‐68 prostate‐specific membrane antigen ((68)Ga‐PSMA) positron‐emission/computed tomography after radical prostatectomy with pathological node‐positive extended lymph node dissection
por: Huits, Thijs H., et al.
Publicado: (2020)

Prostate MRI versus PSA screening for prostate cancer detection (the MVP Study): a randomised clinical trial
por: Nam, Robert, et al.
Publicado: (2022)

Psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutations
por: Bancroft, Elizabeth K., et al.
Publicado: (2018)

The risk of developing cardiovascular disease is increased for patients with prostate cancer who are pharmaceutically treated for depression
por: Wollersheim, Barbara M., et al.
Publicado: (2019)

Prognostic Impact of Different Gleason Patterns on Biopsy Within Grade Group 4 Prostate Cancer
por: Mori, Keiichiro, et al.
Publicado: (2021)

Optimising the number of cores for magnetic resonance imaging‐guided targeted and systematic transperineal prostate biopsy
por: Hansen, Nienke L., et al.
Publicado: (2019)

Patient‐reported ‘ever had’ and ‘current’ long‐term physical symptoms after prostate cancer treatments
por: Gavin, Anna T., et al.
Publicado: (2015)

Genomic “Dark Matter” in Prostate Cancer: Exploring the Clinical Utility of ncRNA as Biomarkers
por: Vergara, Ismael A., et al.
Publicado: (2012)

An observational, multicentre study of cabazitaxel in patients with metastatic castration‐resistant prostate cancer previously treated with docetaxel (CAPRISTANA)
por: Carles, Joan, et al.
Publicado: (2018)

Subtyping of renal cortical neoplasms in fine needle aspiration biopsies using a decision tree based on genomic alterations detected by fluorescence in situ hybridization
por: Gowrishankar, Banumathy, et al.
Publicado: (2014)

The impact of adjuvant therapy in patients with biochemical recurrence on prostate cancer progression and mortality five years after radical prostatectomy
por: Fryczkowski, Mieczysław, et al.
Publicado: (2011)

Patient‐reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of life
por: Lane, Athene, et al.
Publicado: (2016)

Individualised non-contrast MRI-based risk estimation and shared decision-making in men with a suspicion of prostate cancer: protocol for multicentre randomised controlled trial (multi-IMPROD V.2.0)
por: Ettala, Otto, et al.
Publicado: (2022)

Focal Cryoablation of the Prostate: Primary Treatment in 163 Patients With Localized Prostate Cancer
por: Khan, Anwar, et al.
Publicado: (2023)

ReIMAGINE Prostate Cancer Screening Study: protocol for a single-centre feasibility study inviting men for prostate cancer screening using MRI
por: Marsden, Teresa, et al.
Publicado: (2021)

Clinical and Histopathological Characteristics of Prostate Cancer Patients Taken to Palliative Transurethral Prostate Resection
por: Rojas-Manrique, Juan P, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_g6bmgouil4se9i1r6mrd03ailk